Clinical trial Recruiting at 4 sites Interventional Ages 17 to 24

Online program to help prevent sexual assault in college women

Official title: A Randomized Controlled Trial of the Efficacy of IDEA3 - An Evidence-based Sexual Assault Resistance Intervention for Undergraduate Women Adapted for Internet Delivery

Run by University of Maryland, College Park · NCT06058455 · Data updated 2026-11-12

This study tests whether an online program that teaches college women how to resist sexual assault is more effective at preventing victimization than a shorter workshop on consent.

Quick facts

Study typeInterventional
Ages17 Years to 24 Years
SexAll
Enrollment1920 (estimated)
SponsorUniversity of Maryland, College Park
Academic / other
Locations6 sites (Orlando, Florida and 5 other locations)
StatusRecruiting
StartedOctober 2, 2023
Main results expectedSeptember 1, 2027
Study endsDecember 31, 2027
Registry record updatedOctober 21, 2025
Trial IDNCT06058455 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are female-identifying first- and second-year university students aged 17-24 who can attend scheduled program groups.

Probably not a fit

Patients who do not identify as female or are not enrolled in university during the study period may not benefit from this program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial evaluates the effectiveness of the Internet-Delivered Enhanced Assess, Acknowledge, Act (IDEA3) program in reducing sexual violence victimization among undergraduate women. Participants in the intervention group will attend four three-hour sessions focused on sexual assault resistance, while the control group will attend a one-hour consent workshop. The study aims to compare rates of sexual assault victimization between the two groups over a one-year follow-up period. The program is designed to equip young women with skills and knowledge to assess and respond to potentially dangerous situations.

Why it matters

Potential benefit: If successful, this program could significantly reduce the incidence of sexual violence among college women.

How similar studies have gone: Previous studies have shown that similar sexual assault resistance programs can significantly reduce victimization rates, indicating potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1st- and 2nd-year university students at one of the 4 sites
* female-identifying students
* students between ages of 17-24
* able to attend one of the scheduled program groups
* able and willing to be matched with another eligible student

Exclusion Criteria:

\- None

Where it's running

  • University of Central Florida
    Orlando, Florida, United States
    Recruiting
  • University of Maryland
    College Park, Maryland, United States
    Recruiting
  • University of Michigan
    Ann Arbor, Michigan, United States
    Recruiting
  • University of Guelph
    Guelph, Ontario, Canada
    Recruiting
  • University of Nebraska - Lincoln
    Lincoln, Nebraska, United States
    Completed
  • University of Windsor
    Windsor, Ontario, Canada
    Active not recruiting

Study contacts

  • Principal investigator: Sarah M Peitzmeier, PhD — University of Maryland
  • Study coordinator: Sarah M Peitzmeier, PhD
  • Email: speitzme@umd.edu
  • Phone: 301 405 2526

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.